294 related articles for article (PubMed ID: 37335409)
1. Retrospective comparative study of the efficacy of JAK inhibitor (tofacitinib) in the treatment of systemic sclerosis-associated interstitial lung disease.
Junfei Z; Meihua G; Shuai Z; Xiangting L; Zhidan L; Tianming C; Yajing L; Chu T; Lipu S
Clin Rheumatol; 2023 Oct; 42(10):2823-2832. PubMed ID: 37335409
[TBL] [Abstract][Full Text] [Related]
2. KL6 and IL-18 levels are negatively correlated with respiratory function tests and ILD extent assessed on HRCT in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD).
Sieiro Santos C; Antolín SC; Lorenzo JC; Garay CL; Morales CM; de Miguel EB; Guerrero MR; Herránz LS; Álvarez ED
Semin Arthritis Rheum; 2024 Apr; 65():152366. PubMed ID: 38290372
[TBL] [Abstract][Full Text] [Related]
3. Emphysematous change with scleroderma-associated interstitial lung disease: the potential contribution of vasculopathy?
Yamakawa H; Takemura T; Iwasawa T; Yamanaka Y; Ikeda S; Sekine A; Kitamura H; Baba T; Iso S; Okudela K; Kuwano K; Ogura T
BMC Pulm Med; 2018 Jan; 18(1):25. PubMed ID: 29382307
[TBL] [Abstract][Full Text] [Related]
4. JAK inhibitors and systemic sclerosis: A systematic review of the literature.
Moriana C; Moulinet T; Jaussaud R; Decker P
Autoimmun Rev; 2022 Oct; 21(10):103168. PubMed ID: 35944611
[TBL] [Abstract][Full Text] [Related]
5. Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung disease.
Martyanov V; Kim GJ; Hayes W; Du S; Ganguly BJ; Sy O; Lee SK; Bogatkevich GS; Schieven GL; Schiopu E; Marangoni RG; Goldin J; Whitfield ML; Varga J
PLoS One; 2017; 12(11):e0187580. PubMed ID: 29121645
[TBL] [Abstract][Full Text] [Related]
6. Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: a double-blind, placebo-controlled, randomized trial.
Naidu GSRSNK; Sharma SK; Adarsh MB; Dhir V; Sinha A; Dhooria S; Jain S
Rheumatol Int; 2020 Feb; 40(2):207-216. PubMed ID: 31813058
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal Changes in Quantitative Interstitial Lung Disease on Computed Tomography after Immunosuppression in the Scleroderma Lung Study II.
Goldin JG; Kim GHJ; Tseng CH; Volkmann E; Furst D; Clements P; Brown M; Roth M; Khanna D; Tashkin DP
Ann Am Thorac Soc; 2018 Nov; 15(11):1286-1295. PubMed ID: 30265153
[TBL] [Abstract][Full Text] [Related]
8. Worsening of esophageal dilatation is associated with increase in a high-resolution computed tomography (HRCT) score in early systemic sclerosis-associated interstitial lung disease (SSc-ILD).
Wangkaew S; Losuriya P; Euathrongchit J
Clin Rheumatol; 2021 Mar; 40(3):955-963. PubMed ID: 32803568
[TBL] [Abstract][Full Text] [Related]
9. Serum concentration of surfactant protein D in patients with systemic sclerosis: The potential marker of the interstitial lung disease severity.
Grosicka A; Manasar A; Kucharz EJ; Kotyla PJ
Best Pract Res Clin Rheumatol; 2018 Aug; 32(4):541-549. PubMed ID: 31174823
[TBL] [Abstract][Full Text] [Related]
10. Esophageal dilatation and interstitial lung disease in systemic sclerosis: A cross-sectional study.
Richardson C; Agrawal R; Lee J; Almagor O; Nelson R; Varga J; Cuttica MJ; Dematte JD; Chang RW; Hinchcliff ME
Semin Arthritis Rheum; 2016 Aug; 46(1):109-14. PubMed ID: 27033049
[TBL] [Abstract][Full Text] [Related]
11. Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease.
Ebata S; Yoshizaki A; Fukasawa T; Miura S; Takahashi T; Sumida H; Asano Y; Sato S
J Dermatol; 2019 Nov; 46(11):1006-1013. PubMed ID: 31502326
[TBL] [Abstract][Full Text] [Related]
12. High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study.
Wanchu A; Suryanaryana BS; Sharma S; Sharma A; Bambery P
Int J Rheum Dis; 2009 Sep; 12(3):239-42. PubMed ID: 20374353
[TBL] [Abstract][Full Text] [Related]
13. The rationale for targeting the JAK/STAT pathway in scleroderma-associated interstitial lung disease.
Talotta R
Immunotherapy; 2021 Feb; 13(3):241-256. PubMed ID: 33410346
[TBL] [Abstract][Full Text] [Related]
14. Brief Report: Pulmonary Function Tests: High Rate of False-Negative Results in the Early Detection and Screening of Scleroderma-Related Interstitial Lung Disease.
Suliman YA; Dobrota R; Huscher D; Nguyen-Kim TD; Maurer B; Jordan S; Speich R; Frauenfelder T; Distler O
Arthritis Rheumatol; 2015 Dec; 67(12):3256-61. PubMed ID: 26316389
[TBL] [Abstract][Full Text] [Related]
15. Expert consensus on the management of systemic sclerosis-associated interstitial lung disease.
Rahaghi FF; Hsu VM; Kaner RJ; Mayes MD; Rosas IO; Saggar R; Steen VD; Strek ME; Bernstein EJ; Bhatt N; Castelino FV; Chung L; Domsic RT; Flaherty KR; Gupta N; Kahaleh B; Martinez FJ; Morrow LE; Moua T; Patel N; Shlobin OA; Southern BD; Volkmann ER; Khanna D
Respir Res; 2023 Jan; 24(1):6. PubMed ID: 36624431
[TBL] [Abstract][Full Text] [Related]
16. Determinants of impairment in lung diffusing capacity in patients with systemic sclerosis.
Guarnieri G; Zanatta E; Mason P; Scarpa MC; Pigatto E; Maestrelli P; Cozzi F
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S80-6. PubMed ID: 25897784
[TBL] [Abstract][Full Text] [Related]
17. Evolution of Systemic Sclerosis-Associated Interstitial Lung Disease One Year After Hematopoietic Stem Cell Transplantation or Cyclophosphamide.
Ciaffi J; van Leeuwen NM; Boonstra M; Kroft LJM; Schouffoer AA; Ninaber MK; Huizinga TWJ; de Vries-Bouwstra JK
Arthritis Care Res (Hoboken); 2022 Mar; 74(3):433-441. PubMed ID: 32961038
[TBL] [Abstract][Full Text] [Related]
18. Cyclophosphamide for connective tissue disease-associated interstitial lung disease.
Barnes H; Holland AE; Westall GP; Goh NS; Glaspole IN
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD010908. PubMed ID: 29297205
[TBL] [Abstract][Full Text] [Related]
19. Lung magnetic resonance imaging in systemic sclerosis: a new promising approach to evaluate pulmonary involvement and progression.
Gargani L; Bruni C; De Marchi D; Romei C; Guiducci S; Bellando-Randone S; Aquaro GD; Pepe A; Neri E; Colagrande S; Falaschi F; Moggi-Pignone A; Pingitore A; Matucci-Cerinic M
Clin Rheumatol; 2021 May; 40(5):1903-1912. PubMed ID: 33161470
[TBL] [Abstract][Full Text] [Related]
20. Correlation between Interstitial Lung Disease Morphology Scores Based on High-resolution Computed Tomography Chest and Skin Fibrosis Degree Based on Modified Rodnan's Skin Score on Systemic Sclerosis.
Hikmat IH; Ramdhini SS; Soekersi H; Dewi S
Acta Med Indones; 2021 Jul; 53(3):254-260. PubMed ID: 34611063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
